[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anti-bacterial-agents\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anti-bacterial-agents":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,73,109,155,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100510351","preventive-effect-of-prophylactic-oral-antibiotics-against-cholangitis-after-kasai-portoenterostomy-100510351",false,"NCT05925309","Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients whose age of operation is 14-90 d. Sex and race are not restricted;\n* Patients who are born with gestational age older than 36 weeks;\n* Patients whose body weight before operation \\> 2 kg;\n* Patients diagnosed of type-III BA and underwent KP in Children's Hospital of Fudan University;\n* The type-III BA diagnosis is based on cholangiography or operation;\n* Patients whose histological features of liver biopsies are reported. HE staining and Masson staining are required, and edema, inflammation, fibrosis, and hyperplasia of intrahepatic bile duct should be reported;\n* Patients who are not allergic to postoperative medications;\n* Patients who haven't accepted other antibiotic or probiotic therapy.\n\nExclusion Criteria:\n\n* Patients with cholestasis of non-BA disease;\n* Patients who have undergone KP at other institutions;\n* Patients whose pathohistological diagnosis is in doubt;\n* Patients who undergo liver transplantation immediately after KP;\n* Patients with other liver diseases or severe complications (e.g., severe pulmonary hypertension, renal failure, intracranial hemorrhage, etc.) requiring surgical intervention or other medical therapy;\n* Patients with severe cardiac, renal, or central nerve system malformations (e.g., tetralogy of Fallot, transposition of the great arteries, cerebral dysplasia, etc.) and have poor prognosis;\n* Patients judged by the researchers that they can not comply with the study requirements.","ALL","14 Days","90 Days",{"count":20,"type":21},356,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is non-inferiority trial design. This study aimed to investigate the effect of prophylactic oral antibiotics on preventing cholangitis in biliary atresia (BA) patients after Kasai portoenterostomy (KP) by comparing the cholangitis rate in BA patients who received prophylactic oral antibiotics and those who did not. The patients were followed up for 2 years after KP.",[27,28,29],"Biliary Atresia","Cholangitis","Anti-Bacterial Agents","RECRUITING","2026-05-12",{"date":33,"type":34},"2026-05-15","ACTUAL",{"date":36,"type":34},"2023-07-01",{"date":38,"type":21},"2029-12-31",{"name":40,"class":41},"Children's Hospital of Fudan University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":42},"100504291","phase-4-cat-bite-antibiotic-prophylaxis-for-the-handforearm-catbite-100504291","NCT05846399","CAT BITE Antibiotic Prophylaxis for the Hand\u002FForearm (CATBITE)","CAT BITE Antibiotic Prophylaxis and Durations for the Hand\u002FForearm (CATBITE): A Prospective, Randomized, Placebo-controlled, Double-blinded, Clinical Trial","CATBITE","Inclusion Criteria:\n\n* Patients greater or equal to 18 years of age.\n* Bitten by a cat.\n* Location of bite is the hand and\u002For forearm (distal to elbow).\n* Presenting \\\u003C24 hours following a cat bite to the hand\u002Fforearm.\n* English speaking\n\nExclusion Criteria:\n\n* Patients who present with active local or systemic infections\n\n  1. Purulent drainage from the cat bite\n  2. Redness AND swelling at the location of the cat bite\n* Having a fever \\>100.4° F or \\>38° C)-Received antibiotics within the past 30 days\n* Received antibiotics within the past 30 days\n* Patients unwilling to take study medication\n* Patients unwilling to attend scheduled follow-up evaluations or complete study forms\n* Pregnant Women\n* Type I hypersensitivity reaction to any of the study interventions\n* Immunocompromised patients (primary and secondary immunodeficiencies) Primary\n* Autoimmune Lymphoproliferative Syndrome (ALPS)\n* Autoimmune Polyglandular Syndrome type 1 (APS-1)\n* B-cell Expansion with Nuclear factor kappa-light-chain-enhancer of activated B cells and T-cell Anergy (BENTA) Disease\n* Caspase Eight Deficiency State (CEDS)\n* Caspase Recruitment Domain Family Member 9 (CARD9) Deficiency and Other Syndromes of Susceptibility to Candidiasis\n* Cartilage-hair hypoplasia\n* Chédiak-Higashi syndrome\n* Chronic Granulomatous Disease (CGD)\n* Common Variable Immunodeficiency (CVID)\n* Complement Deficiencies\n* Congenital Neutropenia Syndromes\n* Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4) Deficiency\n* Cyclic neutropenia\n* DiGeorge syndrome\n* Dedicator Of Cytokinesis 8 (DOCK8) Deficiency\n* GATA-binding protein 2 (GATA2) Deficiency\n* Glycosylation Disorders with Immunodeficiency\n* Hyper-Immunoglobulin E Syndromes (HIES)\n* Hyper-Immunoglobulin M Syndromes\n* Interferon Gamma, Interleukin 12 and Interleukin 23 Deficiencies\n* Leukocyte Adhesion Deficiency (LAD) Types 1 and 2\n* Lipopolysaccharide Responsive Beige-Like Anchor Protein (LRBA) Deficiency\n* Phosphatidylinositol 3-kinase (PI3-Kinase) Disease\n* Phospholipase C gamma 2 (PLCG2) associated Antibody Deficiency and Immune Dysregulation (PLAID)\n* Severe Combined Immunodeficiency (SCID)\n* Selective Immunoglobulin A (IgA) deficiency\n* Signal transducer and activator of transcription 3 (STAT3) Dominant-Negative Disease\n* STAT3 Gain-of-Function Disease\n* Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome\n* Wiskott-Aldrich Syndrome (WAS)\n* X-Linked Agammaglobulinemia (XLA)\n* X-Linked Lymphoproliferative Disease (XLP)\n* X-linked magnesium transporter 1 (MAGT1) deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect (XMEN) Disease\n* Zeta-associated protein 70 (ZAP-70) deficiency\n\nSecondary\n\n* Malnutrition\n* Uncontrolled Diabetes mellitus\n* Chronic uremia\n* Genetic syndromes: trisomy 21\n* Immunomodulatory, immunosuppressive drug therapy: corticosteroids, calcineurin inhibitors, cytotoxic agents\n* Systemic lupus erythematosus\n* Malignancy\n* Active radiation therapy\n* Bone marrow ablation\n* Infectious diseases: human immunodeficiency virus (HIV) infection, Hepatitis\n\nAdditional Primary and secondary immunodeficiencies can be found at the following link.\n\nhttps:\u002F\u002Fwww.merckmanuals.com\u002Fprofessional\u002Fimmunology-allergic-disorders\u002Fimmunodeficiency-disorders\u002Foverview-of-immunodeficiency-disorders",true,"18 Years",{"count":54,"type":21},72,[56],"PHASE4","Cat bites are puncture wounds that have the potential to seed bacteria deep within the joint capsule, periosteum, and bone. The hand is the most common site of bite injuries. Pasteurella multocida is the is the most common organism isolated from the mouths of cats that can cause infections after a bite. Prophylactic antibiotics are often recommended with amoxicillin-clavulanate for 3-5 days to decrease the incidence of developing an infection. However, only one randomized controlled clinical trial consisting of 12 patients has been performed to justify this course of treatment, raising the possibility that the use of antibiotics could be reduced or even eliminated. Investigators will compare different durations of prophylactic antibiotics and a placebo control for cat bites to the hand\u002Fforearm presenting to the Emergency Department, Urgent Care, Plastic Surgery Clinic using a randomized, controlled, double-blind clinical trial. Participants presenting to the University of Missouri Hospital Emergency Department, Missouri University (MU) Healthcare Urgent Care, Plastic Surgery Clinic over the next year will be offered the chance to enroll if they meet the inclusion\u002Fexclusion criteria. For inclusion, participants will be \\>18 years of age, have cat bites to the hand or distal to elbow, and present within 24 hours of the cat bite injury. Participants must not present with active local or systemic infections, have received antibiotics within the past 30 days, or be immunocompromised (primary and secondary immunodeficiencies). Participants will be randomized to one of three treatment arms (placebo; amoxicillin-clavulanate 1 day; amoxicillin-clavulanate 5 days). Outcomes are the development of an infection at the location of the cat bite and\u002For systemic infection, adverse effects of interventions, disability assessed by Quick Disabilities of Arm, Shoulder and Hand (QuickDASH) scores, and quality of life (QOL) assessed by HAND Questionnaire (HAND-Q) scores. Infection will be assessed at day 0, day 2, day 7+\u002F-2, day 14+\u002F-2, and day 30+\u002F-2 by vital signs, laboratory values, physical examination and with an infrared and digital camera. All measures will be within the standard of care, apart from the infrared camera, QuickDASH, and HAND-Q scores. The anatomic locations of cat bites to the hand\u002Fforearm will be assessed for correlations with infections.",[59,60,61,62,63],"Cat Bite","Hand Injuries","Arm Injury","Infection, Bacterial","Anti-bacterial Agents","2025-10-13",{"date":66,"type":34},"2025-10-15",{"date":68,"type":34},"2023-09-07",{"date":70,"type":21},"2027-08-01",{"name":72,"class":41},"University of Missouri-Columbia",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":92,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100573775","the-impact-of-de-implementing-urine-dipsticks-for-diagnosis-of-utis-in-hospitals-100573775","NCT06750666","The Impact of De-implementing Urine Dipsticks for Diagnosis of UTIs in Hospitals","The Impact of De-implementing Urine Dipsticks for Diagnosis of Urinary Tract Infections in the North Denmark Region: An Interrupted Time-series Analysis","Inclusion Criteria:\n\n* All patients admitted to emergency rooms (≥18 years) from 2019 and forward.\n\nExclusion Criteria:\n\n* Patients directly admitted to an inpatient unit without first visiting an emergency room are excluded from the study.\n* For the primary analysis, only the first admission will be included; subsequent admissions will be excluded.",{"count":81,"type":21},480000,"30 Days","OBSERVATIONAL","The goal of this interrupted time-series analysis is to evaluate the impact of the de-implementation of urine dipsticks as a diagnostic tool for urinary tract infections (UTIs) in hospitalized patients in the North Denmark Region. The main question it aims to answer is:\n\nHow does de-implementation of urine dipsticks affect the diagnosis and management of UTIs and related disorders?\n\nSpecifically, does it change the following parameters:\n\n* Number and severity of UTI infections (lower and upper UTI, non-severe and severe)\n* Antibiotic prescription (overall, antibiotic classes, administration routes, duration, dosages)\n* Number of urine cultures and number of positive urine cultures\n* Risks of admission to intensive care units and 30-day mortality\n* Risk of drug toxicity\n* Length of hospital stay\n* Risk of admission to intensive care unit\n* 30-day risk of readmission after discharge\n* 6-month risks of Clostridioides difficile enterocolitis and de novo antimicrobial resistance in cultures obtained during routine clinical care.\n\nResearchers hypothesize that de-implementing urine dipsticks will lead to a reduced frequency of diagnosed cystitis, reduced antibiotic use, and fewer urine cultures without negatively affecting patient mortality or readmission risk.\n\nResearchers will compare the outcomes before and after the discontinuation of urine dipsticks across hospitals in the North Denmark Region. Furthermore, results will be compared to another Danish administrative healthcare region where dipsticks are still in use as well as urine culture data from the primary sector in the North Denmark Region.\n\nSince this is a registry-based observational study utilizing data from the electronic patient record system in the North Denmark Region, no direct contact will be made with participants.",[86,87,88,29,89,90,91],"Urinary Tract Infections","Diagnostic Techniques and Procedures","Point-of-Care Testing","Registry","Clinical Decision-making","Urinalysis",[93,86,94,95,96,97],"Urine Dipstick De-implementation","Hospital","Registry-Based Study","Clinical Impact","urine dipsticks","NOT_YET_RECRUITING","2025-09-30",{"date":101,"type":34},"2025-10-01",{"date":103,"type":21},"2025-12",{"date":105,"type":21},"2026-12",{"name":107,"class":41},"Jacob Bodilsen",2,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":135,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":42},"100608614","phase-4-modulation-of-gut-microflora-with-rifaximin-to-reduce-high-platelet-reactivity-in-post-acs-patients-on-ticagrelor-100608614","NCT07203846","Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)","FLORA-ACS","Inclusion criteria:\n\n* Between 18 and 80 years of age\n* History of acute coronary syndrome no sooner than 1 month and no later than 12 months prior to study inclusion\n* Current treatment with ticagrelor (90 mg orally twice a day)\n* High platelet reactivity assessed with multiple electrode aggregometry method (AUC of \\>46 U)\n* Provision of informed consent prior to any study procedures\n\nExclusion criteria:\n\n* History of hypersensitivity to rifaximin or other rifamycin-derived agent\n* Ongoing treatment with rifamycins\n* Platelet count \\\u003C 100×10\\^9\u002FL or \\> 450×10\\^9\u002FL\n* Treatment with antibiotics, probiotics, or glucocorticoids within 3 months prior to study inclusion\n* History of gastrointestinal diseases such as inflammatory bowel disease, bowel obstruction, or gastrointestinal tumor\n* Infection, including gastrointestinal infection, within a month prior to study inclusion\n* History of Clostridium difficile infection\n* Current use of specific medications (warfarin, glycoprotein IIb\u002FIIIa inhibitors, immunosuppressants, bile acid sequestrants, antidiarrheal agents)\n* Impaired liver function classified as Child-Pugh class B or C\n* Hemodynamic instability\n* Pregnancy or breastfeeding\n* Patients considered by the investigator to be uncooperative","80 Years",{"count":119,"type":21},50,[56],"The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.",[123,124,125,126,127,128,129,130,131,132,133,29,134],"ACS - Acute Coronary Syndrome","Ticagrelor","Microbiota","Platelet Aggregation","Myocardial Infarction (MI)","Blood Platelets","Drug Effects","Platelet Aggregation Inhibitors","Drug Resistance","Platelet Function Tests","Dysbiosis","Rifaximin",[136,137,138,139,140,141,142,143,144,145],"high platelet reactivity","HPR","Multiplate aggregometry","multiple electrode aggregometry","MEA","microbiome","gut flora","eubiotic","16S rRNA sequencing","P2Y12 inhibitor","2025-09-25",{"date":148,"type":34},"2025-10-02",{"date":150,"type":21},"2026-01-01",{"date":152,"type":21},"2027-06-30",{"name":154,"class":41},"Collegium Medicum w Bydgoszczy",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":42},"100596986","antibiotic-treatment-for-pneumonia-caused-by-stenotrophomonas-maltophilia-in-icu-patients-100596986","NCT07052604","Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients","Inclusion Criteria:\n\n* Adult patients (age ≥ 18 years)\n* Hospitalized in Medical Intensive Care Unit between January 1, 2018, and December 31, 2023\n* Intubated and mechanically ventilated\n* Diagnosed with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia\n\nExclusion Criteria:\n\n* Patients under 18 years old\n* Patients who refuse the use of their data for research purposes",{"count":162,"type":21},300,"This study looks at how different antibiotic treatments affect patients in intensive care who have pneumonia caused by the bacteria Stenotrophomonas maltophilia. It compares using one antibiotic versus two antibiotics, and treatment lengths of 7 days versus 14 days, to see which approach helps patients survive better. The study also examines how resistant the bacteria are to antibiotics and how often the pneumonia comes back.",[165,166,167,29,168],"Pneumonia, Ventilator-Associated","Stenotrophomonas Maltophilia","Intensive Care Units","Drug Resistance, Bacterial","2025-06-26",{"date":171,"type":34},"2025-07-04",{"date":173,"type":34},"2023-12-15",{"date":175,"type":21},"2025-09-15",{"name":177,"class":41},"Centre Hospitalier de Saint-Denis",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":186,"targetDuration":188,"studyType":83,"phases":4,"briefSummary":189,"conditions":190,"keywords":192,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":42},"100461106","prospective-cohort-study-on-antibiotic-course-and-efficacy-after-two-stage-revision-in-pji-100461106","NCT05284318","Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.","Effect of Antibiotic Treatment Course on Clinical Outcome After Two-stage Revision of Prosthetic Joint Infection: A Prospective Cohort Study.","PACER-PJI","Inclusion Criteria:\n\n\\- 1. A diagnosis of PJI was made according to MSIS criteria. 2. Received spacer implantation and a full course of antibiotic treatment (at least 6 weeks), the patient was clinically determined to have infection control and underwent secondary joint revision.\n\n3\\. Age ≥18 years old. 4. The patient voluntarily participated in the study, and was physically and mentally tolerant to the treatment process and various tests of the study. He has signed an informed consent form and passed the examination of all the hospital ethics committees participating in the study.\n\nExclusion Criteria:\n\n* 1\\. Follow-up data not available. 2. Researchers judge that patients no longer meet the standards of the study due to compliance problems",{"count":187,"type":21},500,"2 Years","This is a multicenter prospective cohort study in which patients were evaluated by inclusion and exclusion criteria before phase II revision surgery. Eligible patients will be included in this study after signing the informed consent form. After the second stage revision, according to the patient's symptoms and examination results, the attending physician used a reasonable antibiotic treatment scheme (including intravenous and oral medication). All patients voluntarily participated in the study and signed informed consent. During the treatment period, all prospective patients underwent clinical evaluation at the time points of 1, 3, 6, 12, 18 and 24 months after the start of antibiotic treatment after phase II revision. The infection control rate of patients was evaluated by follow-up at least 2 years after operation, so as to analyze the effect of antibiotic treatment course after two-stage revision of periprosthetic joint infection.",[191,29],"Periprosthetic Joint Infection",[193,194,29],"Periprosthetic joint infection","Second-stage revision","2022-03-09",{"date":197,"type":34},"2022-03-17",{"date":199,"type":34},"2021-12-01",{"date":201,"type":21},"2026-12-31",{"name":203,"class":41},"First Affiliated Hospital of Fujian Medical University"]